# SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

> **NCT05345327** · PHASE3 · RECRUITING · sponsor: **The George Institute** · enrollment: 994 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT05345327
- **Lead sponsor:** The George Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 994 (ESTIMATED)
- **Last updated:** 2024-12-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05345327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05345327, "SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05345327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*